NBTX Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

49.998

Open

46.640

VWAP

48.08

Vol

128.41K

Mkt Cap

2.34B

Low

46.000

Amount

6.17M

EV/EBITDA(TTM)

Total Shares

48.50M

3.91B

EV/OCF(TTM)

P/S(TTM)

245.47

Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Events Timeline

(ET)

2026-05-04

17:40:00

Nanobiotix Announces FDA Acceptance of NANORAY-312 Protocol Amendment

2026-03-30 (ET)

2026-03-30

07:50:00

Nanobiotix Presents Initial Data on JNJ-1900 Clinical Trial

News

9.0

05-05NASDAQ.COM

Nanobiotix Receives FDA Approval for Study Protocol Amendment

9.0

05-04Newsfilter

Nanobiotix Announces FDA Acceptance of Protocol Amendment for NANORAY-312 Clinical Trial

8.5

04-20NASDAQ.COM

Nanobiotix Unveils Preclinical Data for Nanoprimer Platform

3.5

04-20Newsfilter

Nanobiotix's Nanoprimer Enhances LNP-DNA Delivery for Cancer Therapy

9.5

04-01NASDAQ.COM

Nanobiotix Reports Narrowed Net Loss and Cash Runway Guidance

9.5

03-31seekingalpha

Nanobiotix Reports FY 2025 Financial Results

1 Analyst Rating

Wall Street analysts forecast NBTX stock price to rise

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

3.50

Averages

3.50

High

3.50

Current: 0.000

Low

3.50

Averages

3.50

High

3.50

UBS

Neutral

maintain

$30

AI Analysis

2026-05-01

Reason

UBS

Price Target

$30

AI Analysis

2026-05-01

maintain

Neutral

Reason

UBS raised the firm's price target on Nanobiotix (NBTX) to $30 from $3.50 and keeps a Neutral rating on the shares. Shares have surged over the past year on improved biotech sentiment and de-risking events including Johnson & Johnson's (JNJ) involvement and a non-dilutive royalty financing deal, but with Phase 3 NANORAY-312 data not expected until 1H27, the stock appears fairly valued with limited near-term upside and a binary longer-term outcome tied to trial results, the analyst tells investors in a research note.

H.C. Wainwright

Swayampakula Ramakanth

Buy

maintain

2026-04-13

Reason

H.C. Wainwright

Swayampakula Ramakanth

Price Target

2026-04-13

maintain

Buy

Reason

H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Nanobiotix to EUR 34 from EUR 32 and keeps a Buy rating on the shares. The firm says the company is "evolving from a single-asset radiotherapy company into a platform-driven biotech through the advancement of its Curadigm Nanoprimer technology."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for NBTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for Nanobiotix SA (NBTX.O) is 77.52, compared to its 5-year average forward P/E of -1.59. For a more detailed relative valuation and DCF analysis to assess Nanobiotix SA's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.59

Current PE

77.52

Overvalued PE

77.59

Undervalued PE

-80.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-5.73

Current EV/EBITDA

-28.61

Overvalued EV/EBITDA

13.20

Undervalued EV/EBITDA

-24.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

51.47

Current PS

53.49

Overvalued PS

122.22

Undervalued PS

-19.28

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

what should I buy for quick gains

Intellectia · 50 candidates

Region: USPrice: >= $15.00Rsi Category: moderateRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $8.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 3,000,000

Ticker

Name

Market Cap$

FLNC

Fluence Energy Inc

4.65B

Babcock & Wilcox Enterprises Inc

2.57B

NAMS

NewAmsterdam Pharma Company NV

4.63B

IPI

Intrepid Potash Inc

587.70M

WRBY

Warby Parker Inc

3.53B

LUNR

Intuitive Machines Inc

7.03B

buy or hold

Intellectia · 100 candidates

Price: >= $-100.00Rsi Category: moderateMoving Average Relationship: PriceAboveMA20Ema 60: >= -100Macd: positiveNews Driver: Positive

Ticker

Name

Market Cap$

BDSX

Biodesix Inc

113.91M

CIFR

Cipher Digital Inc

7.26B

LIND

Lindblad Expeditions Holdings Inc

1.17B

IIPR

Innovative Industrial Properties Inc

1.51B

PLOW

Douglas Dynamics Inc

1.03B

WAT

Waters Corp

29.63B

Stocks bullish for 2+ years

Intellectia · 1147 candidates

Moving Average Relationship: PriceAboveMA20, PriceAboveMA200Quarter Price Change Pct: >= $0.00Ytd Price Change Pct: >= $5.00Year Price Change Pct: >= $25.00

Ticker

Name

Market Cap$

PTN

Palatin Technologies Inc

36.42M

AXTI

AXT Inc

4.83B

Babcock & Wilcox Enterprises Inc

2.13B

MGRT

Mega Fortune Co Ltd

1.93B

SNDK

Sandisk Corp

137.63B

RLMD

Relmada Therapeutics Inc

760.44M

top moving stocks

Intellectia · 31 candidates

Market Cap: >= 500.00MPrice: >= $2.00Price Change Pct: $-100.00 - $-5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000

Ticker

Name

Market Cap$

LNN

Lindsay Corp

1.22B

KNF

Knife River Corp

4.65B

OMER

Omeros Corp

869.71M

WIX

Wix.Com Ltd

5.28B

IRWD

Ironwood Pharmaceuticals Inc

635.93M

PBH

Prestige Consumer Healthcare Inc

2.73B

stocks gain $5.00 in 2026

Intellectia · 2622 candidates

Year Price Change Pct: >= $0.01

Ticker

Name

Market Cap$

AXTI

AXT Inc

3.80B

PTN

Palatin Technologies Inc

35.18M

RGC

Regencell Bioscience Holdings Ltd

12.08B

RLMD

Relmada Therapeutics Inc

639.83M

Babcock & Wilcox Enterprises Inc

1.95B

TERN

Terns Pharmaceuticals Inc

5.44B

Whales Holding NBTX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nanobiotix SA (NBTX) stock price today?

The current price of NBTX is 48.24 USD — it has decreased -9.92

What is Nanobiotix SA (NBTX)'s business?

What is the price predicton of NBTX Stock?

Wall Street analysts forecast NBTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NBTX is3.50 USD with a low forecast of 3.50 USD and a high forecast of 3.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Nanobiotix SA (NBTX)'s revenue for the last quarter?

Nanobiotix SA revenue for the last quarter amounts to NaN USD, decreased

What is Nanobiotix SA (NBTX)'s earnings per share (EPS) for the last quarter?

Nanobiotix SA. EPS for the last quarter amounts to USD, decreased

How many employees does Nanobiotix SA (NBTX). have?

Nanobiotix SA (NBTX) has 97 emplpoyees as of May 13 2026.

What is Nanobiotix SA (NBTX) market cap?

Today NBTX has the market capitalization of 2.34B USD.

NBTX Overview

NBTX Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding NBTX

Trading Trends

People Also Watch

Frequently Asked Questions

What is Nanobiotix SA (NBTX) stock price today?

What is Nanobiotix SA (NBTX)'s business?

What is the price predicton of NBTX Stock?

What is Nanobiotix SA (NBTX)'s revenue for the last quarter?

What is Nanobiotix SA (NBTX)'s earnings per share (EPS) for the last quarter?

How many employees does Nanobiotix SA (NBTX). have?

What is Nanobiotix SA (NBTX) market cap?